



FEP Medical Policy Manual

FEP 7.01.93 Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency-Coblation (Nucleoplasty)

Effective Policy Date: July 1, 2022

Original Policy Date: December 2011

Related Policies:

7.01.18 - Automated Percutaneous and Percutaneous Endoscopic Discectomy

7.01.72 - Percutaneous Intradiscal Electrothermal Annuloplasty, Radiofrequency Annuloplasty, Biacuplasty and Intraosseous Basivertebral Nerve Ablation

Decompression of the Intervertebral Disc Using Laser Energy (Laser Discectomy) or Radiofrequency-Coblation (Nucleoplasty)

Description

Description

Laser energy (laser discectomy) and radiofrequency coblation (nucleoplasty) are being evaluated for decompression of the intervertebral disc. For laser discectomy under fluoroscopic guidance, a needle or catheter is inserted into the disc nucleus, and a laser beam is directed through it to vaporize tissue. For disc nucleoplasty, bipolar radiofrequency energy is directed into the disc to ablate tissue. These minimally invasive procedures are being evaluated for the treatment of discogenic back pain.

OBJECTIVE

The objective of this evidence review is to evaluate whether laser discectomy or disc nucleoplasty with radiofrequency coblation improve the net health outcome in patients who have discogenic back pain.

POLICY STATEMENT

Laser discectomy and radiofrequency coblation (disc nucleoplasty) are considered **investigational** as techniques of disc decompression and treatment of associated pain.

POLICY GUIDELINES

None

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

A number of laser devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for incision, excision, resection, ablation, vaporization, and coagulation of tissue. Intended uses described in FDA summaries include a wide variety of procedures, including percutaneous discectomy. Trimedyne received 510(k) clearance in 2002 for the Trimedyne Holmium Laser System Holmium: Yttrium, Aluminum Garnet (Holmium:YAG), in 2007 RevoLix Duo™ Laser System, and in 2009 Quanta System LITHO Laser System. All were cleared, based on equivalence with predicate devices for percutaneous laser disc decompression/discectomy, including foraminoplasty, percutaneous cervical disc decompression/discectomy, and percutaneous thoracic disc decompression/discectomy. The summary for the Trimedyne system states that indications for cervical and thoracic decompression/discectomy include uncomplicated ruptured or herniated discs, sensory changes, imaging consistent with findings, and symptoms unresponsive to 12 weeks of conservative treatment. Indications for treatment of cervical discs also include positive nerve conduction studies. FDA product code: GEX.

In 2001, the Perc-D SpineWand™ (ArthroCare) was cleared for marketing by FDA through the 510(k) process. FDA determined that this device was substantially equivalent to predicate devices. It is used in conjunction with the ArthroCare Coblation System 2000 for ablation, coagulation, and decompression of disc material to treat symptomatic patients with contained herniated discs. Smith & Nephew acquired ArthroCare in 2014; as of 2017, Smith & Nephew has not provided any information about coblation devices specific to spine surgeries on its website. FDA product code: GEI.

RATIONALE

Summary of Evidence

For individuals who have discogenic back pain or radiculopathy who receive laser discectomy, the evidence includes systematic reviews of observational studies. Relevant outcomes are symptoms, functional outcomes, and treatment-related morbidity. While numerous case series and uncontrolled studies have reported improvements in pain levels and functioning following laser discectomy, the lack of well-designed and -conducted controlled trials limits interpretation of reported data. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have discogenic back pain or radiculopathy who receive disc nucleoplasty with radiofrequency coblation, the evidence includes randomized controlled trials (RCTs) and systematic reviews. Relevant outcomes are symptoms, functional outcomes, and treatment-related morbidity. For nucleoplasty, there are 3 RCTs in addition to several uncontrolled studies. These RCTs are limited by the lack of blinding, an inadequate control condition in 1, inadequate data reporting in the second, and low enrollment with early study termination in the third. The available evidence is insufficient to permit conclusions concerning the effect of these procedures on health outcomes due to multiple confounding factors that may bias results. High-quality randomized trials with adequate follow-up (at least 1 year), which control for selection bias, the placebo effect, and variability in the natural history of low back pain, are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in "Supplemental Information" if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

National Institute for Health and Care Excellence

In 2016, NICE updated its guidance on laser lumbar discectomy for the treatment of sciatica.¹⁴ The guidance stated that current evidence "is inadequate in quantity and quality."

Also in 2016, NICE also updated its guidance on percutaneous disc decompression using coblation for lower back pain and sciatica in 2016.¹⁵ NICE stated: "Current evidence on percutaneous coblation of the intervertebral disc for low back pain and sciatica raises no major safety concerns. The evidence on efficacy is adequate and includes large numbers of patients with appropriate follow-up periods." The guidance also noted that the patient should be informed of the range of treatment options available.

American Society of Interventional Pain Physicians

In 2009, updated in 2013, the American Society of Interventional Pain Physicians issued practice guidelines on lumbar disc compression and chronic spinal pain.^{16,17} The systematic reviews informing the 2013 guidelines found limited evidence for percutaneous laser disc decompression and limited to fair evidence for nucleoplasty.^{2,7}

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

The Centers for Medicare & Medicaid Services have determined that thermal intradiscal procedures, including percutaneous (or plasma) disc decompression or coblation, are not reasonable and necessary for the treatment of low back pain. Therefore, thermal intradiscal procedures, which include procedures that "employ the use of a radiofrequency energy source or electrothermal energy to apply or create heat and/or disruption within the disc for the treatment of low back pain, are noncovered."¹⁸

The Centers for Medicare & Medicaid Services has not published a national coverage decision on laser discectomy; however, the Centers did indicate the following in its decision on laser procedures:

"Medicare recognizes the use of lasers for many medical indications. Procedures performed with lasers are sometimes used in place of more conventional techniques. In the absence of a specific noncoverage instruction, and where a laser has been approved for marketing by the Food and Drug Administration, Medicare Administrative contractor discretion may be used to determine whether a procedure performed with a laser is reasonable and necessary and, therefore, covered."¹⁹

REFERENCES

1. Singh V, Manchikanti L, Benyamin RM, et al. Percutaneous lumbar laser disc decompression: a systematic review of current evidence. *Pain Physician*. May-Jun 2009; 12(3): 573-88. PMID 19461824
2. Singh V, Manchikanti L, Calodney AK, et al. Percutaneous lumbar laser disc decompression: an update of current evidence. *Pain Physician*. Apr 2013; 16(2 Suppl): SE229-60. PMID 23615885
3. Gibson JN, Waddell G. Surgical interventions for lumbar disc prolapse. *Cochrane Database Syst Rev*. Apr 18 2007; (2): CD001350. PMID 17443505
4. Tassi GP. Comparison of results of 500 microdiscectomies and 500 percutaneous laser disc decompression procedures for lumbar disc herniation. *Photomed Laser Surg*. Dec 2006; 24(6): 694-7. PMID 17199468
5. Choy DS. Percutaneous laser disc decompression: an update. *Photomed Laser Surg*. Oct 2004; 22(5): 393-406. PMID 15671712
6. Menchetti PP, Canero G, Bini W. Percutaneous laser discectomy: experience and long term follow-up. *Acta Neurochir Suppl*. 2011; 108: 117-21. PMID 21107947
7. Manchikanti L, Falco FJ, Benyamin RM, et al. An update of the systematic assessment of mechanical lumbar disc decompression with nucleoplasty. *Pain Physician*. Apr 2013; 16(2 Suppl): SE25-54. PMID 23615886
8. Gerszten PC, Smuck M, Rathmell JP, et al. Plasma disc decompression compared with fluoroscopy-guided transforaminal epidural steroid injections for symptomatic contained lumbar disc herniation: a prospective, randomized, controlled trial. *J Neurosurg Spine*. Apr 2010; 12(4): 357-71. PMID 20201654
9. Chitragran R, Poopitaya S, Tassanawipas W. Result of percutaneous disc decompression using nucleoplasty in Thailand: a randomized controlled trial. *J Med Assoc Thai*. Oct 2012; 95 Suppl 10: S198-205. PMID 23451463
10. de Rooij J, Harhangi B, Aukes H, et al. The Effect of Percutaneous Nucleoplasty vs Anterior Discectomy in Patients with Cervical Radicular Pain due to a Single-Level Contained Soft-Disc Herniation: A Randomized Controlled Trial. *Pain Physician*. Nov 2020; 23(6): 553-564. PMID 33185372
11. Bokov A, Skorodumov A, Isrelov A, et al. Differential treatment of nerve root compression pain caused by lumbar disc herniation applying nucleoplasty. *Pain Physician*. Sep-Oct 2010; 13(5): 469-80. PMID 20859316
12. Birnbaum K. Percutaneous cervical disc decompression. *Surg Radiol Anat*. Jun 2009; 31(5): 379-87. PMID 19190848
13. Cuellar VG, Cuellar JM, Vaccaro AR, et al. Accelerated degeneration after failed cervical and lumbar nucleoplasty. *J Spinal Disord Tech*. Dec 2010; 23(8): 521-4. PMID 21131800
14. National Institute for Health and Care Excellence (NICE). Epiduroscopic lumbar discectomy through sacral hiatus for sciatica [IPG570]. 2016; <https://www.nice.org.uk/guidance/ipg570>. Accessed March 10, 2022.
15. National Institute for Health and Care Excellence (NICE). Percutaneous coblation of the intervertebral disc for low back pain and sciatica [IPG543]. 2016; <https://www.nice.org.uk/guidance/ipg543>. Accessed March 11, 2022.
16. Manchikanti L, Derby R, Benyamin RM, et al. A systematic review of mechanical lumbar disc decompression with nucleoplasty. *Pain Physician*. May-Jun 2009; 12(3): 561-72. PMID 19461823
17. Manchikanti L, Abdi S, Atluri S, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations. *Pain Physician*. Apr 2013; 16(2 Suppl): S49-283. PMID 23615883
18. Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD) for Laser Procedures (140.5). 1997; <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=69&ncdver=1&DocID=140.5&bc=gAAAAAgAAAAAA%3D%3D>. Accessed March 11, 2022.
19. Centers for Medicare and Medicaid Services (CMS). National Coverage Determination (NCD) for Thermal Intradiscal Procedures (TIPs) (150.11). 2009; <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=324>. Accessed March 12, 2022.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
December 2011	New policy	
June 2012	Replace policy	Policy statement changed to not medically necessary. Related policies added. Literatures search. Reference 16 added.
September 2013	Replace policy	Policy updated with literature review; references 2, 13-15 and 23 added; policy statement unchanged.
September 2014	Replace policy	Policy updated with literature review; policy statement unchanged.
September 2015	Replace policy	Policy updated with literature review; no references added. Policy statement unchanged.
March 2017	Replace policy	Policy updated with literature review through November 7, 2016; Rationale revised and some references removed. Policy statement unchanged.
June 2018	Replace policy	Policy updated with literature review through February 5, 2018; no references added. Policy statement unchanged.
June 2019	Replace policy	Policy updated with literature review through February 5, 2019; no references added. Policy statement unchanged.
June 2020	Replace policy	Policy updated with literature review through February 11, 2020; no references added. Policy statements unchanged.
June 2021	Replace policy	Policy updated with literature review through February 25, 2021; reference added. Policy statements unchanged.
June 2022	Replace policy	Policy updated with literature review through January 17, 2022; no references added. Policy statements unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.